Aptar’s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA‑051 Nasal Spray

Crystal Lake, Illinois, March 19, 2026 - AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that its Unidose (UDS) Powder Nasal Spray System is being utilized in ENA Respiratory’s Phase II clinical study of INNA 051, an investigational nasal spray being evaluated for its potential to help protect against symptomatic viral respiratory infections. This collaboration reflects the growing role of intranasal delivery technologies in supporting the development of novel, non-vaccine approaches to respiratory disease prevention.

ENA Respiratory, a clinical‑stage pharmaceutical company developing antiviral host defense enhancers intended to help minimize the impact of symptomatic viral respiratory infections, recently announced the dosing of the first participants in its Phase II study of INNA‑051. The Phase II study is assessing the safety, tolerability and potential effectiveness of the company’s once‑weekly nasal spray in adults at increased risk of exposure to viral respiratory infections. The community‑based study is designed to evaluate the potential of INNA-051 to help reduce the burden of symptomatic respiratory viral illness.

Aptar Pharma’s UDS powder nasal delivery system is designed to deliver a single, precise dose of dry powder with consistent intranasal performance, intended to support consistent administration in clinical development settings. The ready-to-use system is designed to be simple to operate and well suited for nasal powder formulations that may benefit from enhanced stability.

The nasal delivery system will be housed in Aptar CSP Technologies’ innovative container closure system, featuring fully-integrated 3-Phase Activ-Polymer™ technology designed to protect the powder formulation against moisture. The system was designed with internal features to prevent premature actuation from device insertion, removal, or dropping, supporting reliable patient access to the drug.

“Aptar Pharma is proud to support ENA Respiratory in the clinical development of INNA-051 through the use of our UDS powder nasal delivery system,” said Alex Theodorakis, President, Aptar Pharma Prescription. “By combining reliable intranasal delivery technologies with comprehensive technical and regulatory expertise, we help our partners advance innovative therapies intended to address unmet needs in respiratory health.”

Download full press release.